RxDoctor Payments DataLook up a doctor →

Farshad Rashidian, DO

Interventional Pain Medicine · West Chester, PANPI 1639582067

Payments from drug & device makers

$19,087in general payments, 2019–2025

Across 406 payments — averaging $47.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$14K
  • Nevro Corp.$853
  • Medtronic$729
  • Vertiflex, Inc.$642
  • Boston Scientific$571
  • Vertos Medical, Inc.$492
  • plus $2K from 28 others

What the payments were for

  • Travel & lodging$8,59145%
  • Food & beverage$10,49655%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,087 in reported general payments places this provider in the 85th percentile of 59 interventional pain medicine providers in Pennsylvania.

See all interventional pain medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$374,370
Medicare patients
356
Services billed
7,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen337$6,311
LyricaPregabalin11$5,290
MovantikNaloxegol Oxalate11$4,495
Gabapentin333$4,170
Oxycodone Hcl218$3,329
Tizanidine Hcl281$2,843
Pregabalin196$2,659
Duloxetine Hcl105$1,946
Cyclobenzaprine Hcl133$1,587
Diclofenac Sodium17$1,268
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen70$1,213
Morphine Sulfate ErMorphine Sulfate27$693
Meloxicam127$633
Morphine Sulfate17$555
Tramadol Hcl57$394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLyrica$81$5,29011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 59 interventional pain medicine providers in Pennsylvania.

Other interventional pain medicine in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →